Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Multiple Myeloma 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 2Carcinoma, Non-Small-Cell Lung 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lung Neoplasms 1Locally Recurrent Skin Squamous Cell Carcinoma 1Leukemia, Plasma Cell 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Classic Follicular Lymphoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 91Carboplatin 79Specimen Handling 76Magnetic Resonance Spectroscopy 64Pemetrexed 60Cisplatin 49durvalumab 44Paclitaxel 38Nivolumab 34atezolizumab 32Radiotherapy 30Radiosurgery 30osimertinib 29Blood Specimen Collection 27Biopsy 26Gemcitabine 24Docetaxel 24Immunoglobulin G 23Standard of Care 22Disulfides 22Etoposide 21Drug Therapy 21Taxes 18Practice Guidelines as Topic 18Radiation 17Educational Status 16130-nm albumin-bound paclitaxel 15X-Rays 14Surveys and Questionnaires 14Bevacizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Hyaluronoglucosaminidase × 1 year × Clear all
NCT05340309 2026-01-29

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

University of Southern California

Phase 2 Active not recruiting
5 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡